Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis

Drugs
K Wellington, Blair Jarvis

Abstract

Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is a nonsteroid, has anti-inflammatory activity, and has demonstrated efficacy in reducing symptoms of atopic dermatitis in adult and paediatric patients when applied topically. Compared with vehicle, topical pimecrolimus 1.0% cream was significantly more effective at reducing symptoms of atopic dermatitis, as measured by the Eczema Area and Severity Index (EASI), in infants aged 3 to 23 months, children aged 2 to 17 years and adults. The median reductions from baseline in the total EASI score in adults after treatment with pimecrolimus 1.0% or corresponding vehicle twice daily for 3 weeks were 47 and 0%, respectively. In infants and children, treatment with pimecrolimus 1.0% twice daily for 6 weeks resulted in significant decreases in mean EASI scores compared with vehicle. The severity of pruritus was significantly reduced in patients of all age groups after topical treatment with pimecrolimus 1.0% cream. Compared with vehicle, the incidence of eczematous flares was also reduced by intermittent long-term use of topical pimecrolimus 1.0% in adults, children and infants. Sixty percent of children treated with pimecrolimus for 1 year completed the first 6 months of treatment w...Continue Reading

Associated Clinical Trials

References

Aug 1, 1991·Pediatric Clinics of North America·J M Hanifin
Dec 1, 1987·Journal of the American Academy of Dermatology·J L SeymourM C Milligan
May 1, 1974·The British Journal of Dermatology·J J LeydenA M Kligman
Apr 8, 1998·BMJ : British Medical Journal·P H Howarth
May 16, 1998·BMJ : British Medical Journal·P S Friedmann
Feb 17, 1999·The British Journal of Dermatology·U MrowietzE Christophers
Sep 1, 1999·The British Journal of Dermatology·M GrassbergerG Zenke
Nov 4, 2000·Expert Opinion on Investigational Drugs·C PaulA Stuetz
Apr 12, 2001·The British Journal of Dermatology·J HarperP Burtin
Apr 12, 2001·The British Journal of Dermatology·T LugerJ D Bos
Jul 7, 2001·American Journal of Therapeutics·A M Fendrick, J L Baldwin
Feb 9, 2002·Dermatology : International Journal for Clinical and Investigative Dermatology·Edwin J M Van LeentJan D Bos
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·K Wellington, C M Spencer

❮ Previous
Next ❯

Citations

Nov 25, 2004·Experimental Dermatology·M GrassbergerT A Luger
Jan 25, 2005·American Journal of Clinical Dermatology·Keri Wellington, Stuart Noble
Dec 3, 2009·Journal of Neurosurgery. Spine·Berker CemilIbrahim Tekdemir
Sep 14, 2011·The Mount Sinai Journal of Medicine, New York·Andrew SohnGary Goldenberg
Aug 21, 2003·American Journal of Clinical Dermatology·Gil Yosipovitch, Alan Fleischer
Feb 7, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Richard G B LangleyCarle Paul
Sep 15, 2009·Clinical and Experimental Dermatology·J-C Li, A-E Xu
Sep 6, 2003·Advances in Therapy·Alexander K C Leung, Kirk A Barber
Mar 7, 2013·Expert Opinion on Pharmacotherapy·Jean Ayer, Helen S Young
Apr 12, 2006·American Journal of Clinical Dermatology·Jann LübbeUNKNOWN NOBEL (New Online Based ELidel) Study Group
Apr 2, 2003·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·R Niedner
Nov 17, 2011·Cutaneous and Ocular Toxicology·Yunes PanahiAmirhossein Sahebkar
Jul 24, 2013·Expert Opinion on Drug Metabolism & Toxicology·Hanna PruchaClaudia Traidl-Hoffmann
Jul 11, 2006·Current Allergy and Asthma Reports·Jonathan M Spergel, Donald Y M Leung
Aug 24, 2006·International Archives of Allergy and Immunology·Anton StuetzJosef G Meingassner
Sep 15, 2005·Rheumatology·A Tlacuilo-ParraM Salazar-Páramo
Aug 11, 2004·American Journal of Clinical Dermatology·Michael IskedjianThomas R Einarson
Mar 4, 2008·Journal of the European Academy of Dermatology and Venereology : JEADV·T Zuberbier, M Bräutigam
Jan 8, 2021·Therapeutics and Clinical Risk Management·Celina DubinEmma Guttman-Yassky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Related Papers

American Journal of Clinical Dermatology
Keri Wellington, Blair Jarvis
American Journal of Clinical Dermatology
Keri Wellington, Stuart Noble
Expert Opinion on Pharmacotherapy
Klaus Wolff, A Stuetz
Dermatology : International Journal for Clinical and Investigative Dermatology
Lawrence F EichenfieldC F Paul
© 2022 Meta ULC. All rights reserved